Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q2 FY26 Earnings Presentation
8 slides from Orchid Pharma's earnings presentation, Nov 11, 2025
Slide 1: Investors Presentation - Quarter II and half year ended September 30, 2025
November 11, 2025 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (
Slide 2: Financials Q2 FY-26
Orchid Pharma Limited Financials Q2 FY-26 • All results in standalone basis. • These are approx. or exact nos. pls refer financials for details.
Slide 3: Financial Performance
Financial Performance (Amt. in Cr.) Q2-26 Q2-25 Change % H1-26 H1-25 % Change Sales 194 223 -13% 366 467 -22% Other Income 15 8 +88% 31 16 +94% COGS 132 131 +1% 231 281 -18% Employee Exp 24 21 +14% 46 42 +10% Other Exp 38 41 -7% 76 81 -6% EBITDA* 15 38 -61% 44 79 -44% % to Sales 8% 17% 12% 17% Inter
Slide 4: Turnover (Amt. in Cr.)
Turnover (Amt. in Cr.) 250 223 199 194 200 165 150 122 100 50 - Q2-22 Q2-23 Q2-24 Q2-25 Q2-26
Slide 5: EBITDA, PBT & PAT as % to Sales
EBIDTA, PBT & PAT as % to Sales Q2-26 20% 17% 15% 16% 15% 11% 10% 10% 11% 10% 8% 8% 5% 1% 1% 0% -2% -2% -5% -10% -15% -17% -17% -20% Q2-22 Q2-23 Q2-24 Q2-25 Q2-26 EBITDA 8% 15% 16% 17% 8% PBT -17% -2% 10% 11% 1% PAT -17% -2% 10% 11% 1% EBITDA PBT PAT
Slide 6: P&L Analysis – Gross Margin % to Sales
P&L Analysis – Gross Margin % to Sales Q2-26 45% 41% 41% 39% 38% 40% 35% 32% 30% 25% 20% 15% 10% 5% 0% Q2-22 Q2-23 Q2-24 Q2-25 Q2-26
Slide 7: P&L Analysis – Exp. % to Sales
P&L Analysis – Exp. % to Sales Q2-26 25% 22% 20% 20% 18% 18% 19% 15% 13% 12% 11% 9% 9% 10% 5% 0% Q2-22 Q2-23 Q2-24 Q2-25 Q2-26 Emp Benefit Other Exp
Slide 8: Thank You
Thank You